Genotypic Analysis of Drug-Resistant HIV Cost-Effective

Article

WESTPORT, Conn-Genotypic analysis of drug-resistant HIV strains appears to be cost-effective.

A new study conducted by Milton C. Weinstein, MD, from the Harvard School of Public Health, used an HIV simulation model to incorporate data from several HIV-related trials to analyze the cost-effectiveness of genotypic resistance testing. HIV-infected subjects with baseline CD4 counts of 250 cells per microliter were the target group.

Researchers found that testing following antiretroviral failure increased life expectancy by 3 months and cost $17,900 per quality-adjusted-life-year (QALY) gained. The figure for primary resistance testing was $22,300 with 20% prevalence of primary resistance, but increased to $69,000 when prevalence was assumed to be only 4%.

The cost per QALY gained never exceeded $25,000 when effectiveness, multiple cost factors, quality-of-life weights, and discount rates were varied.

Information from www.hivandhepatitis.com

Recent Videos
The CDC’s updated hospital respiratory reporting requirement has added new layers of responsibility for infection preventionists. Karen Jones, MPH, RN, CIC, FAPIC, clinical program manager at Wolters Kluwer, breaks down what it means and how IPs can adapt.
Studying for the CIC using a digital tablet and computer (Adobe Stock 335828989 by NIKCOA)
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Cheron Rojo, BS, FCS, CHL,  CER, CFER, CRCST
Matthias Tschoerner, Dr Sc
Standardizing Cleaning and Disinfection
Concept images of Far-UVC  (Adobe Stock 316993517 by hopenv)
Physicians Sound Alarm: Vaccine Misinformation and Policy Failures Threaten US Public Health
Anna Castillo-Gutierrez, CRCST, CSPDT, CHL, CIS, CFER,  and Maya Luera, CRCST, CIS, CER, CHL
Related Content